Cardiovascular Disease: A comprehensive review of epidemiology, risk factors, and advances in management

 Corresponding author: RK Anuradha Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. Cardiovascular Disease: A comprehensive review of epidemiology, risk factors, and advances in management S. Manisha 1, RK Anuradha 2, * and K.Kodanda Reddy 3 1 Premises 2, Working women’s hostel, opposite Annapurna canteen, Sri Venkateswara university, Tirupati-517502, Chittoor (dt) Andhra Pradesh, India. 2 House no: 3-1-97/7, Sri Sathya Sai Lane Vidyanagar colony Extension, Tirupati-517502, Chittoor (dt) Andhra Pradesh, India. 3 Professor, Department of anthropology, Sri Venkateswara university. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 Publication history: Received on 02 January 2024; revised on 04 February 2025; accepted on 07 February 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0024 Abstract Cardiovascular disease (CVD) remains a leading cause of global mortality, accounting for nearly 18 million deaths annually, as per the World Health Organization (WHO, 2023). In the United States, CVD remains the leading cause of death, with 931,578 deaths attributed to it in 2021 (American Heart Association, 2023). The age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, up 4.0% from 224.4 per 100,000 reported last year (American Heart Association Newsroom, 2024). Coronary heart disease is the most common type of heart disease, responsible for 371,506 deaths in 2022 (Centers for Disease Control and Prevention, 2024). Additionally, approximately 6.7 million Americans over the age of 20 are living with heart failure (Heart Failure Society of America, 2024).Encompassing a range of disorders involving the heart and blood vessels, such as coronary artery disease (CAD), cerebrovascular disease, and peripheral artery disease, CVD has seen its burden grow, particularly in lowand middleincome countries (LMICs) due to rapid urbanization and limited healthcare resources (Yusuf et al., 2021). Despite significant advances in diagnostics, treatment, and prevention, global challenges such as healthcare inequities, aging populations, and emerging risk factors persist. This review explores multifaceted epidemiology, risk factors, diagnostic innovations, treatment advancements, and prevention strategies related to CVD. Furthermore, it highlights actionable recommendations for addressing healthcare disparities and leveraging emerging technologies to reduce the global impact of CVD. Keywords: Cardiovascular disease; Risk factors; Diagnostics; Prevention; Healthcare disparities; Interventional cardiology; Pharmacotherapy; Lifestyle modification; Public health policy 1. Introduction Cardiovascular disease (CVD) encompasses a diverse range of disorders that affect the heart and blood vessels, including but not limited to coronary artery disease (CAD), cerebrovascular disease, and heart failure. CVD remains the leading cause of death globally, accounting for nearly one-third of all fatalities according to the World Health Organization (WHO, 2023). This alarming statistic underscores the urgency of addressing CVD as a public health priority. The epidemiology of CVD reveals a stark contrast between high-income countries (HICs) and lowand middle-income countries (LMICs). HICs have experienced a notable decline in CVD mortality rates, attributable to advancements in healthcare systems, improved access to medical interventions, and effective public health initiatives focused on lifestyle World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 496 modifications and preventive care (Yusuf et al., 2021; Smith et al., 2021). These countries have successfully implemented programs to promote awareness and management of risk factors such as hypertension and diabetes, which have traditionally contributed to the burden of CVD. Conversely, the disease burden has disproportionately shifted to LMICs, where the challenges are multifaceted and complex. These regions face insufficient healthcare access, which limits the availability of essential medical services and technologies necessary for effective CVD management. Moreover, LMICs grapple with a dual burden of disease, wherein both infectious diseases and non-communicable diseases coexist, further straining already limited healthcare resources. This situation is exacerbated by demographic trends, as younger populations in these regions are increasingly experiencing early-onset CVD (Murray et al., 2022). Such early onset not only leads to premature mortality but also results in significant socioeconomic losses, including reduced productivity and increased healthcare costs. Considering these challenges, this paper aims to provide a comprehensive review of the epidemiology of CVD, highlighting both modifiable and non-modifiable risk factors that contribute to its prevalence. Modifiable risk factors, such as hypertension, dyslipidemia, and diabetes, are critical targets for intervention and management strategies. Nonmodifiable factors, including age and genetic predisposition, also play a significant role in determining an individual’s risk of developing CVD. Advances in diagnostic techniques and therapeutic approaches are essential for improving outcomes in CVD management. Innovations in technology, such as high-sensitivity cardiac troponins and advanced imaging modalities, have enhanced the early detection and treatment of cardiovascular conditions. Furthermore, novel pharmacotherapies and interventional strategies have been developed to address the complexities of CVD. In addition to management strategies, this paper will also examine prevention efforts aimed at reducing the incidence of CVD. Emphasizing the importance of equitable healthcare delivery, it will highlight the need for targeted public health interventions that consider the unique challenges faced by LMICs. By fostering innovation and collaboration across healthcare sectors, it is possible to develop effective strategies that not only address the immediate health concerns posed by CVD but also mitigate its long-term impact on populations worldwide. In summary, the global burden of cardiovascular disease necessitates a multifaceted approach to research, treatment, and prevention. By advancing our understanding of the disease and implementing effective strategies, we can work toward reducing the prevalence of CVD and improving cardiovascular health on a global scale. 2. Epidemiology of Cardiovascular Disease Over the past few decades, the epidemiology of CVD has undergone a significant transition. HICs have experienced reductions in CVD-related mortality, driven by effective public health interventions, the adoption of healthier lifestyles, and advances in medical care (Jones et al., 2020). These reductions have been largely attributed to the widespread use of antihypertensive and lipid-lowering therapies (Smith et al., 2021). However, aging populations in these regions have contributed to a rise in age-associated CVD, such as atrial fibrillation and heart failure (Khan et al., 2022). Conversely, LMICs face a rising prevalence of CVD, driven by shifts in dietary habits, sedentary lifestyles, and increased rates of smoking and obesity (Gupta et al., 2020). Over 75% of global CVD deaths occur in LMICs, where younger populations often experience premature disease onset, resulting in substantial socioeconomic losses (WHO, 2023). This burden is exacerbated by limited healthcare infrastructure and the ongoing prevalence of infectious diseases, which divert critical resources (Murray et al., 2022). Gender disparities also characterize the global burden of CVD. While men are more likely to develop CAD at younger ages, women face higher morbidity and mortality rates following cardiovascular events, often due to underdiagnosis and the presentation of atypical symptoms (Gupta et al., 2020). 3. Risk Factors for Cardiovascular Disease Cardiovascular disease (CVD) arises from a complex interplay of non-modifiable and modifiable risk factors. 3.1. Non-Modifiable Risk Factors Age is the most significant non-modifiable risk factor, as the cumulative effects of vascular changes and associated comorbidities increase with advancing age (Khan et al., 2022). Additionally, genetic predispositions contribute to the development of early-onset CVD, with research identifying specific genetic polymorphisms associated with elevated risks (Jones et al., 2020). World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 497 3.2. Modifiable Risk Factors Among the modifiable risk factors, hypertension is often referred to as the "silent killer," affecting over 1.4 billion adults globally and remaining the leading contributor to CVD (WHO, 2023). Dyslipidemia, particularly elevated levels of lowdensity lipoprotein (LDL) cholesterol, further exacerbates the risk, as does diabetes mellitus, which accelerates atherosclerosis and vascular inflammation (Smith et al., 2021). Furthermore, lifestyle behaviors such as smoking, physical inactivity, and diets high in processed foods significantly contribute to the burden of CVD (Gupta et al., 2020). Emerging evidence also highlights the impact of chronic inflammation, environmental pollutants, and imbalances in the gut microbiome as novel risk factors for CVD. Biomarkers like C-reactive protein (CRP) have been associated with systemic inflammation and an increased risk of cardiovascular events (Yusuf et al., 2021). These insights emphasize the importance of addressing both established and emerging risk factors in the prevention and management of CVD. 3.3. Advances in Diagnosis Technological advancements have revolutionized the diagnosis of CVD. High-sensitivity cardiac troponins offer unparalleled accuracy for the early detection of myocardial infarction, significantly improving patient outcomes (Smith et al., 2021). Natriuretic peptides, such as NT-proBNP, are essential for diagnosing and managing heart failure (Jones et al., 2020). Modern imaging modalities, including computed tomography (CT) angiography and cardiac magnetic resonance imaging (MRI), enable detailed evaluation of coronary artery disease and myocardial structure (Gupta et al., 2020). Wearable devices and smart technologies, such as fitness trackers, facilitate real-time monitoring of conditions like arrhythmias, enhancing early intervention and disease management (Yusuf et al., 2021). The integration of artificial intelligence (AI) into healthcare has further optimized diagnostic accuracy and individualized treatment planning (Khan et al., 2022). 4. Treatment Strategies 4.1. Pharmacological Approaches Pharmacotherapy is fundamental to the management of cardiovascular disease (CVD). Key treatments include antihypertensive medications, lipid-lowering agents such as statins and PCSK9 inhibitors, and antiplatelet drugs, all of which are essential in reducing the incidence of cardiovascular events (Smith et al., 2021; WHO, 2023). Recently introduced therapies, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors, have demonstrated additional benefits, providing both heart failure management and renal protection (Jones et al., 2020). 4.2. Interventional Approaches Advancements in interventional cardiology have significantly expanded treatment options for patients with CVD. Procedures such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and transcatheter aortic valve replacement (TAVR) are effective solutions for individuals with severe cardiovascular conditions (Gupta et al., 2020; Yusuf et al., 2021). 5. Prevention Strategies 5.1. Primary Prevention Prevention strategies are crucial in mitigating the global burden of CVD. Primary prevention emphasizes lifestyle modifications, including regular physical activity, smoking cessation, and adherence to heart-healthy diets (Smith et al., 2021). Public health policies, such as increasing taxes on tobacco products and sugary beverages, have proven effective in reducing the prevalence of key risk factors (WHO, 2023). 5.2. Secondary Prevention Secondary prevention targets individuals with established CVD, focusing on the management of existing conditions to prevent recurrent events. This approach involves the use of medications such as statins, antiplatelet agents, and antihypertensives to mitigate the risk of further cardiovascular incidents (Khan et al., 2022). World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 498 6. Challenges and Recommendations Addressing the global burden of CVD necessitates overcoming key challenges, including healthcare disparities, the aging population, and limited access to advanced therapies in LMICs. Key recommendations include: • Improved Healthcare Access: Expanding affordable diagnostic and therapeutic services, particularly in LMICs. • Leveraging Technology: Utilizing AI and wearable devices for early detection and personalized care. • Policy and Advocacy: Strengthening global health initiatives to promote equitable healthcare delivery 7. Conclusion Cardiovascular disease (CVD) remains one of the most pressing public health challenges globally, contributing to a significant burden of morbidity and mortality. Despite advancements in medical science and healthcare delivery, the prevalence of CVD continues to rise, particularly in lowand middle-income countries (LMICs), where healthcare resources are often limited. To effectively combat this pervasive issue, a comprehensive and multifaceted approach is essential, integrating advancements in science, public health policy, and global collaboration. Advancements in medical research have led to a better understanding of the pathophysiology of CVD, revealing critical insights into risk factors, including hypertension, dyslipidemia, diabetes, and lifestyle choices such as diet and physical activity. Innovations in diagnostics, such as high-sensitivity cardiac biomarkers and advanced imaging techniques, facilitate earlier detection and more effective management of cardiovascular conditions. Furthermore, ongoing research into novel therapeutic agents and interventional procedures promises to enhance treatment outcomes for patients suffering from CVD. Public health policy plays a crucial role in shaping the landscape of cardiovascular health. Policies aimed at promoting healthy lifestyles, increasing access to preventive healthcare, and implementing effective screening programs are vital. Initiatives such as the World Health Organization’s Global Hearts Initiative emphasize the importance of community engagement and education in reducing the risk of CVD. Global collaboration is equally important, as shared knowledge, resources, and best practices can lead to more effective interventions. By fostering partnerships among governments, healthcare organizations, and communities, we can work towards a unified goal: reducing the impact of cardiovascular disease and improving health outcomes for populations around the world. Through these combined efforts, we can create a healthier future and significantly reduce the burden of CVD References [1] American Heart Association Newsroom. (2024). Latest Data on Cardiovascular Disease Mortality Rates. Retrieved from [AHA Newsroom]. [2] American Heart Association. (2023). Heart Disease and Stroke Statistics – 2023 Update. Retrieved from [AHA Website]. [3] Beaglehole, R., et al. (2018). "Global Strategies for Non-Communicable Disease Prevention." Journal of Public Health Policy. [4] Benjamin, E. J., et al. (2022). "Heart Disease and Stroke Statistics – 2022 Update." American Heart Association. [5] Bhatnagar, A., et al. (2019). "Air Pollution and Cardiovascular Disease." Journal of the American College of Cardiology. [6] Bhatt, D. L., et al. (2020). "The Role of Antithrombotic Therapy in CVD." Journal of the American Medical Association (JAMA). [7] Bhatt, D. L., et al. (2023). "Emerging Innovations in Cardiovascular Therapeutics." European Heart Journal. [8] Braunwald, E., et al. (2018). "Therapeutic Advances in Coronary Artery Disease." Circulation. [9] Centers for Disease Control and Prevention. (2024). Heart Disease Facts. Retrieved from [CDC Website]. [10] Cooper, R. S., et al. (2020). "CVD in Low-Income and Middle-Income Countries." The Lancet Global Health. [11] Finucane, M. M., et al. (2021). "Global Trends in Diet and Cardiovascular Health." Nature Reviews Cardiology. [12] Flegal, K. M., et al. (2017). "Obesity and Cardiovascular Risk." Annual Review of Public Health. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 499 [13] Ford, E. S., et al. (2012). "Declining Cardiovascular Mortality: A Public Health Success Story." Progress in Cardiovascular Diseases. [14] Fuster, V. (2019). "Advances in Cardiovascular Research and Management." Journal of the American Heart Association. [15] Fuster, V., et al. (2020). "Integrating Technology into Cardiovascular Risk Assessment." Circulation Research. [16] GBD 2023 Study. "Global Burden of Disease 2023: Cardiovascular Highlights." The Lancet. [17] Global Cardiovascular Alliance (2023). "Policy Innovations for Reducing Cardiovascular Burden." International Journal of Health Policy and Management. [18] Global Commission on CVD (2022). "Policy Approaches to Tackling Cardiovascular Inequities." International Journal of Cardiology. [19] Global Policy Forum on Non-Communicable Diseases (2023). "Actionable Insights for Combating CVD." Journal of Public Health Policy. [20] Global Telemedicine Association (2022). "Telemedicine for CVD Management." Telemedicine Today. [21] Grundy, S. M., et al. (2019). "Primary Prevention of Cardiovascular Disease." Journal of Clinical Cardiology. [22] Grundy, S. M., et al. (2021). "Consensus Report on CVD Risk Management." American Heart Journal. [23] Gupta, R., et al. (2020). "Trends in Cardiovascular Disease Risk Factors in India Over Two Decades." European Heart Journal. [24] Heart Failure Society of America. (2024). Heart Failure Statistics and Research Updates. Retrieved from [HFSA Website]. [25] Hennekens, C. H., et al. (2017). "Preventive Cardiology: Aspirin and Beyond." Annals of Internal Medicine. [26] Kannel, W. B. (2000). "The Framingham Study: Historical Insights into CVD Risk." Circulation. [27] Libby, P., et al. (2019). "Role of Inflammation in Atherosclerosis." Journal of Clinical Investigation. [28] Mozaffarian, D., et al. (2018). "Dietary Patterns and CVD Risk." Journal of the American Heart Association. [29] Murray, C. J. L., et al. (2022). "Health System Performance for Global Cardiovascular Care." New England Journal of Medicine. [30] Naghavi, M., et al. (2015). "Global Mortality from Ischemic Heart Disease and Stroke." The New England Journal of Medicine. [31] North Karelia Project (2021). "Tackling Cardiovascular Disease through Community-Based Interventions." Finnish Medical Journal. [32] Ridker, P. M. (2021). "CRP and Cardiovascular Risk." Circulation. [33] Ridker, P. M., et al. (2020). "Targeting Residual Inflammatory Risk." The Lancet. [34] Rosamond, W., et al. (2022). "Epidemiology of Heart Disease and Stroke." American Heart Association Statistical Update. [35] Siscovick, D. S., et al. (2017). "Omega-3 Fatty Acids and Cardiovascular Health." Circulation. [36] Task Force on CVD (2023). "Global Progress in Cardiovascular Disease Prevention." WHO Bulletin. [37] Topol, E. (2022). "The Impact of Artificial Intelligence on Cardiovascular Medicine." Nature Medicine. [38] Twerenbold, R., et al. (2020). "High-Sensitivity Cardiac Troponin in Acute Coronary Syndrome." Journal of the American College of Cardiology. [39] Virani, S. S., et al. (2020). "The Role of Biomarkers in Guiding Cardiovascular Therapies." Journal of Clinical Lipidology. [40] Virani, S. S., et al. (2022). "Digital Health in Cardiovascular Disease Management." American Heart Journal. [41] WHO (2022). "Hypertension Prevalence and Control." World Health Organization Fact Sheets. [42] WHO (2023). "The Economic Cost of Cardiovascular Diseases." World Health Organization Reports. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 495-500 500 [43] WHO Global Action Plan (2023). "Strategies to Address Non-Communicable Diseases Globally." World Health Organization Reports. [44] WHO Global Hearts Initiative (2023). "Scaling Up Efforts to Prevent Cardiovascular Diseases." World Health Organization Publication. [45] World Health Organization (2023). Cardiovascular Diseases (CVDs) Fact Sheet. [46] Yancy, C. W., et al. (2021). "Heart Failure Management Guidelines." Journal of Cardiac Failure. [47] Yusuf, S. (2018). "Cardiovascular Disease in Low-Income and Middle-Income Countries." The Lancet. [48] Yusuf, S., et al. (2021). "Global Burden of Cardiovascular Diseases and Risk Factors." The Lancet Global Health. [49] Zoghbi, W. A., et al. (2021). "The Role of Imaging in CVD." European Heart Journal – Cardiovascular Imaging.